Indeed, an increasing number of cases have reported that advanced EGFR-mutant NSCLC patients that developed concomitant BRAF mutations following acquired resistance to EGFR-TKI treatment exhibit durable responses and good tolerance to combined EGFR and BRAF inhibitors treatment (Aboubakar Nana and Ocak, 2021; Ribeiro et al., 2021; Schaufler et al., 2021). This evidence concerns the gene BRAF and non-small cell lung carcinoma.